Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis

References

• Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J. Autoimmun.35(1), 10–14 (2010).
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum.62(9), 2569–2581 (2010).
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther.11(3), 229–244 (2009).
   PubMed Web of Science ®Google Scholar
• Dale J, Porter D. Optimising the strategy of care in early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol.24(4), 443–455 (2010).
   PubMedGoogle Scholar
• Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis.69(4), 631–637 (2010).
   PubMed Web of Science ®Google Scholar
• Feely MG, O’Dell JR. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. Curr. Opin. Rheumatol.22(3), 316–320 (2010).
   PubMedGoogle Scholar
• Mease PJ. Improving the routine management of rheumatoid arthritis: the value of tight control. J. Rheumatol.37(8), 1570–1578 (2010).
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum.59(6), 762–784 (2008).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis.69(6), 964–975 (2010).
   PubMed Web of Science ®Google Scholar
• Bykerk V. Unmet needs in rheumatoid arthritis. J. Rheumatol. Suppl.82, 42–46 (2009).
   PubMedGoogle Scholar
• Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum.38(6), 727–735 (1995).
   PubMed Web of Science ®Google Scholar
• van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum.41(10), 1845–1850 (1998).
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther.11(Suppl. 1), S1 (2009).
   PubMed Web of Science ®Google Scholar
• Papagoras C, Voulgari PV, Drosos AA. Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis. Autoimmun. Rev.9(8), 574–582 (2010).
   PubMed Web of Science ®Google Scholar
• Feely MG. New and emerging therapies for the treatment of rheumatoid arthritis. Open Access Rheumatology: Research and Reviews2, 35–43 (2010).
   PubMedGoogle Scholar
• Lindstrom TM, Robinson WH. Amultitude of kinases – which are the best targets in treating rheumatoid arthritis? Rheum. Dis. Clin. North Am.36(2), 367–383 (2010).
   PubMed Web of Science ®Google Scholar
• Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat. Rev. Drug Discov.9(4), 257–258 (2010).
   PubMed Web of Science ®Google Scholar
• Sato K, Tsuchiya M, Saldanha J et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res.53(4), 851–856 (1993).
   PubMed Web of Science ®Google Scholar
• Hushaw LL, Sawaqed R, Sweis G et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther. Clin. Risk Manag.6, 143–152 (2010).
   PubMed Web of Science ®Google Scholar
• Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics2(1), 75–82 (2008).
   PubMedGoogle Scholar
• Matsumoto T, Tsurumoto T, Shindo H. Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. Rheumatol. Int.26(12), 1096–1100 (2006).
   PubMedGoogle Scholar
• Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol. Int.13(2), 45–51 (1993).
   PubMed Web of Science ®Google Scholar
• Milman N, Karsh J, Booth RA. Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem.43(16–17), 1309–1314 (2010).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. In: Therapeutic Antibodies. Handbook of Experimental Pharmacology 181. Chernajovsky Y, Nissim A (Eds). Springer-Verlag, Berlin, Germany, 151–160 (2008).
   Google Scholar
• Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine77(3), 201–205 (2010).
   PubMed Web of Science ®Google Scholar
• Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert. Opin. Ther Targets11(5), 613–624 (2007).
   PubMed Web of Science ®Google Scholar
• Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J. Health Syst Pharm.65(15), 1413–1418 (2008).
   PubMed Web of Science ®Google Scholar
• Nakamura I, Omata Y, Naito M, Ito K. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J. Rheumatol.36(2), 459–460 (2009).
   PubMed Web of Science ®Google Scholar
• Biffl WL, Moore EE, Moore FA, Barnett CC Jr. Interleukin-6 suppression of neutrophil apoptosis is neutrophil concentration dependent. J. Leukoc. Biol.58(5), 582–584 (1995).
   PubMed Web of Science ®Google Scholar
• McLoughlin RM, Hurst SM, Nowell MA et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J. Immunol.172(9), 5676–5683 (2004).
   PubMed Web of Science ®Google Scholar
• Milovanovic M, Nilsson E, Jaremo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim. Acta.343(1–2), 237–240 (2004).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood112(10), 3959–3964 (2008).
   PubMed Web of Science ®Google Scholar
• Schmitt C, Kuhn B, Banken L, Kivitz A, Zhang X, Grange S. Drug-disease interaction between tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacol. Ther.89(5), 735–740 (2010).
   Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet371(9617), 987–997 (2008).
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis.69(1), 88–96 (2010).
   PubMed Web of Science ®Google Scholar
• Levi M, Frey N, Grange S, Schwab D, Woodworth T. Effect of tocilizumab exposure on IL-6 receptor levels in patients with rheumatoid arthritis: graphical analysis of pooled data from four Phase III clinical trials. Ann. Rheum. Dis.67(Suppl. II), 192 (2008).
   Google Scholar
• Levi M, Frey N, Grange S, Schwab D, Woodworth T. Reduction in inflammatory biomarkers with increasing exposure to the IL-6 inhibitor, tocilizumab, in patients with rheumatoid arthritis: graphical analysis of pooled data. Ann. Rheum. Dis.67(Suppl. II), 192 (2008).
   Google Scholar
• Morcos P, Zhang X, Grange S, Schmitt C. Relationship of tocilizumab dose and neutrophil counts. Presented at: 73rd Annual Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals. Philadelphia, PA, USA, 16–21 October 2009.
   Google Scholar
• Robak T, Gladalska A, Stepien H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm.7(5), 347–353 (1998).
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis.67(11), 1516–1523 (2008).
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum.58(10), 2968–2980 (2008).
   PubMed Web of Science ®Google Scholar
• Uchiyama Y, Yoshida H, Koike N et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int. Immunopharmacol.8(11), 1595–1601 (2008).
   PubMed Web of Science ®Google Scholar
• Hashizume M, Mihara M. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling. Rheumatol. Int.29(4), 397–401 (2009).
   PubMedGoogle Scholar
• Grange S, Schmitt C, Ludger B, Kuhn B, Zhang X. Thorough QT/QTC study of tocilizumab after single-dose administration at therapeutic and supra therapeutic doses in healthy subjects. Int. J. Clin. Pharmacol. (2011) (In press).
   Google Scholar
• Levi M. Tocilizumab 8mg/kg monthly dosing induce a sustained reduction in C-reactive protein (CRP) levels in patients with rheumatoid arthritis (RA). Presented at: 110 Annual Meeting for American Society of Clinical Pharmacology and Therapeutics. National Harbour, MD, USA, 18–21 March 2009.
   Google Scholar
• Actemra® prescribing information. Genentech, Inc., a member of the Roche Group, South San Francisco, CA, USA (2010).
   Google Scholar
• Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J. Clin. Pharmacol.50(7), 754–766 (2010).
   PubMed Web of Science ®Google Scholar
• Grange S, Kuhn B, Riek M et al. A randomized, double blind, placebo controlled, parallel group study to investigate the safety, tolerability, and pharmacokinetics of tocilizumab following ascending single dose administration in healthy subjects. Presented at: 110th Annual Meeting for American Society of Clinical Pharmacology and Therapeutics. National Harbor, MD, USA, 18–21 March 2009.
   Google Scholar
• Schmitt C, Kuhn B, Zhang X, Kivitz A, Grange, S. Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Int. J. Clin. Pharm. Ther. (2011) (In Press).
   PubMedGoogle Scholar
• Zhang X, Schmitt C, Grange S et al. Disease-drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo. Presented at: 110th Annual Meeting for American Society of Clinical Pharmacology and Therapeutics. National Harbor, MD, USA, 18–21 March 2009.
   Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol.30(7), 1426–1435 (2003).
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum.46(12), 3143–3150 (2002).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum.50(6), 1761–1769 (2004).
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum.54(9), 2817–2829 (2006).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis.68(10), 1580–1584 (2009).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis.66(9), 1162–1167 (2007).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol.19(1), 12–19 (2009).
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Burgos-Vargas R, Skopouli FN et al. Tocilizumab inhibits radiographic progression, improves physical function, and gains efficacy over time: LITHE 2 year. Presented at: EULAR (European League Against Rheumatism) Annual European Congress of Rheumatology. Rome, Italy, 16–19 June 2010.
   Google Scholar
• Yazici Y, Curtis JR, Ince A et al. Tocilizumab is effective as early as 4 weeks with continued and increased response at 6 months: a randomised, double-blind study in patients with moderate to severe active RA: The ROSE Study. Presented at: American College of Rheumatology Annual Meeting. Atlanta, GA, USA, 7–11 November 2010.
   Google Scholar
• Hashimoto J, Garnero P, van der Heijde D et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod. Rheumatol.21(1), 10–15 (2010).
   PubMedGoogle Scholar
• Kremer JM, Blanco R, Brzosko M et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum.63(3), 609–621 (2011).
   PubMed Web of Science ®Google Scholar
• Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum.62(1), 33–43 (2010).
   PubMed Web of Science ®Google Scholar
• Levi M, Frey N, Grange S, Woodworth T. Relationship between serum concentration of the interleukin-6 receptor inhibitor, tocilizumab (TCZ), and disease activity score (DAS28) in patients with rheumatoid arthritis. Presented at: Annual Meeting of the Population Approach Group in Europe. Marseille, France, 18–20 June 2008.
   Google Scholar
• Cosson V, Frey N, Grange S, Schwab D, Woodworth T. Population PK/PD analysis of the relationship between tocilizumab exposure and neutrophil count in patients with rheumatoid arthritis. Ann. Rheum. Dis.67(Suppl. II), 192 (2008).
   Google Scholar
• Genovese MC, Smolen JS, Emery P et al. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low-density lipoprotein cholesterol: analysis of five Phase 3 clinical trials. Presented at: American College of Rheumatology (ACR) 72nd Annual Scientific Meeting. San Francisco, CA, USA, 24–29 October 2008.
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation106(25), 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Actemra® prescribing information. : Hoffmann-La Roche Limited, Ontario, Canada (2010).
   Google Scholar
• Actemra® prescribing information. Roche Products Pty Limited., Australia (2010).
   Google Scholar
• Actemra® prescribing information. Chugai Pharmaceutical Co., Ltd., Tokyo, Japan (2008).
   Google Scholar